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DOI 10.1016/j.ccr.2010.04.012SUMMARYMLL is involved in chromosomal rearrangements that generate fusion proteins with deregulated transcrip-
tional activity. The mechanisms of MLL fusion protein-mediated transcriptional activation are poorly under-
stood. Here we show MLL interacts directly with the polymerase associated factor complex (PAFc) through
sequences flanking the CxxC domain. PAFc interacts with RNA polymerase II and stimulates posttransla-
tional histone modifications. PAFc augments MLL and MLL-AF9 mediated transcriptional activation of
Hoxa9. Conversely, knockdown of PAFc disrupts MLL fusion protein-mediated transcriptional activation
and MLL recruitment to target loci. PAFc gene expression is downregulated during hematopoiesis and likely
serves to regulateMLL function. Deletions ofMLL that abolish interactions with PAFc also eliminateMLL-AF9
mediated immortalization indicating an essential function for this interaction in leukemogenesis.INTRODUCTION
MLL is a histone methyltransferase containing a C-terminal SET
domain that methylates histone H3 lysine 4, a mark commonly
associated with gene activation (Milne et al., 2002; Nakamura
et al., 2002; Strahl et al., 1999). MLL is required for normal
embryonic development through proper maintenance of
patterns of Hox gene expression (Yu et al., 1995). MLL also plays
a central role in regulating hematopoietic stem cell self-renewal
and progenitor expansion (Jude et al., 2007; McMahon et al.,
2007). The protein is of particular biomedical importance
because rearrangements involving MLL located at chromosome
11q23 are one of the most common genetic alterations in human
leukemia. Although the mechanisms are likely to differ, all rear-
ranged forms of MLL positively upregulate expression of HOX
genes including HOXA9 and the HOX cofactor MEIS1, which
has been shown to be critical for transformation (Armstrong
et al., 2002; Ayton and Cleary, 2003; Kumar et al., 2004). The
most commonMLL rearrangements are balanced translocationsSignificance
Translocations involving theMLL gene create potent oncogen
leukemias, underscoring the importance of understanding the
biochemical approacheswe have identified direct physical inte
retained inMLL fusion proteins. At amolecular level we showPA
tional activation and for proper recruitment of MLL to target
co-factor for MLL fusion proteins that is necessary in vivo for c
tive new therapeutic target for leukemias with MLL rearrangemthat account for up to 80% of infant acute leukemia and approx-
imately 5%–10% of adult acute myeloid leukemia (AML) and
acute lymphoid leukemia (ALL) cases (Aplan, 2006; Hess,
2004). The resulting oncogenic fusion proteins fuse approxi-
mately 1400 N-terminal amino acids of MLL in frame to one of
over 60 different translocation partners (Krivtsov and Armstrong,
2007). The breakpoint cluster region in MLL invariably includes
the CxxC domain and adjacent RD2 region in MLL fusion
proteins, but deletes the downstream PHD fingers and SET
domain (Zhang and Rowley, 2006). Because the SET domain is
lost during rearrangement, MLL fusion proteins activate tran-
scription through mechanisms dependent on the translocation
partner. The most common of these fusion proteins involve
translocations between MLL and nuclear translocation partners
including AF9, AF4, and ENL, among others, that interact with
a complex of proteins termed ENL associated proteins (EAPs)
or a closely related complex called AEP for AF4 family/ENL
family/P-TEFb complex (Yokoyama et al., 2010). In addition to
the most common MLL translocation partners, EAP includesic fusion proteins that account for up to 80% of infant acute
molecular mechanisms driving oncoprotein function. Using
raction of the PAF complex (PAFc) with sequences invariably
Fc is required for full MLL fusion proteinmediated transcrip-
genes. This study demonstrates that PAFc is an essential
ell immortalization and consequently may serve as an attrac-
ents.
Cancer Cell 17, 609–621, June 15, 2010 ª2010 Elsevier Inc. 609
Cancer Cell
MLL Requires the PAF Complex for Leukemogenesisthe histone H3 lysine 79 methyltransferase hDOT1L and tran-
scription elongation factors CDK9 and cyclinT1 (collectively
known as pTEFb) (Krivtsov et al., 2008; Mueller et al., 2007).
Several structural domains have been identified in MLL and
MLL fusion proteins that are required for transcriptional activity.
Identifying these domains and their molecular interactions is
important because of their promise for therapeutic targeting.
For example, interaction of N-terminal sequences of MLL in a
trimolecular complex with Menin and LEDGF is required for tar-
geting the fusion protein to chromatin and for leukemogenicity
(Caslini et al., 2007; Yokoyama and Cleary, 2008; Yokoyama
et al., 2005). The DNA methyltransferase homology region or
CxxC domain of MLL binds nonmethylated CpG islands and
protects against DNA methylation (Ayton et al., 2004; Erfurth
et al., 2008). Point mutations that block DNA binding by this
region also block immortalization (Ayton et al., 2004).
In addition to the CxxC domain itself, regions immediately
adjacent to the CxxC domain also appear to be important for
MLL function. In the study by Bach et al. involving domain swaps
between MLL1 and MLL2, the CxxC domain along with flanking
sequences of MLL1 were essential for immortalization by MLL
fusion proteins (Bach et al., 2009). In particular, immortalization
was dependent on MLL sequences between amino acids (aa)
1149 and 1154 (the so-called pre-CxxC domain) as well as
sequences in the adjacent basic ‘‘post-CxxC’’ or RD2 region
between aa 1298 and 1337 (Ayton et al., 2004; Bach et al., 2009).
Increasing evidence shows that both histone H3 lysine 4
(H3K4) methylation, which is mediated by MLL, among other
methyltransferases, and histone H3 lysine 79 (H3K79) methyla-
tion-mediated by DOT1L, which is recruited by MLL fusion
proteins, is dependent on histone H2B monoubiquitination.
The polymerase associated factor complex (PAFc) plays a critical
role in mediating H2B ubiquitination as well as promoting
H3K4 and H3K79 methylation (Dover et al., 2002; Krogan et al.,
2003; Ng et al., 2003; Sun and Allis, 2002). PAFc is composed
of five subunits in mammals including PAF1, LEO1, CDC73,
CTR9, and WDR61 (Rozenblatt-Rosen et al., 2005; Zhu et al.,
2005a).
The role of PAFc in transcriptional regulation is beginning to
be better defined. PAFc was originally identified as a protein
complex in yeast that associates with RNA polymerase II
(RNAP II) (Wade et al., 1996). The complex associates with
both initiating (Ser5-phosphorylated) and elongating (Ser2-
phosphorylated) RNAPII (Pokholok et al., 2002). Increasing
evidence suggests that in mammals many genes controlling
development, including the Hox genes, are regulated at the level
of transcriptional elongation (Chopra et al., 2009). At such
‘‘pause prone’’ promoters, RNA polymerase II (RNAPII) interacts
with two complexes that inhibit transcriptional elongation, nega-
tive elongation factor (NELF) and DRB sensitivity-inducing factor
(DSIF). NELF is a complex of four subunits that binds to the
unphosphorylated RNAPII C-terminal domain (CTD) and induces
proximal promoter pausing. DSIF is composed of a heterodimer
of hSpt4 and hSpt5 that plays a dual role in both transcriptional
activation and repression. hSpt5 contains six copies of the
sequence G-S-R/Q-T-P (the C-terminal repeats or CTR), which
is similar in sequence to the RNAPII CTD Y-S-P-T-S-P-S.
When the CTR is unphosphorylated, DSIF represses transcrip-
tional elongation. As an early step in transcriptional activation,610 Cancer Cell 17, 609–621, June 15, 2010 ª2010 Elsevier Inc.pTEF-b phosphorylates both the Pol II CTD as well as the
hSpt5 CTR. CTD phosphorylation releases NELF. Importantly
phosphorylation of the hSpt5 CTR in DSIF also promotes recruit-
ment of PAFc (Liu et al., 2009).
Once recruited, PAFc then has two critical activities. One is the
recruitment of the E2 ubiquitin ligase RAD6 and the E3 ubiquitin
ligase BRE1 (in mammals hBRE1A/RNF20 and BRE1B/RNF40),
which is mediated through either a direct or indirect interaction
between PAF1 and BRE1 (Kim et al., 2009; Pavri et al., 2006).
Importantly, the interaction with PAF1 not only recruits BRE1
and RAD6 but also stimulates the ubiquitinating activity of the
heterocomplex for histone H2B lysine 120. In yeast this is
followed by recruitment of the proteosomal ATPases Rpt4 and
Sug1 (Rpt6) and methylation by the yeast MLL complex homolog
COMPASS, which is recruited by interaction with monoubiquiti-
nated histone H2B via the Cps35 subunit as well as through
PAF1 (Krogan et al., 2003; Lee et al., 2007). However, the human
homolog of Cps35, WDR82, doesn’t interact with MLL com-
plexes (Wu et al., 2008), suggesting that MLL is recruited by
alternative mechanisms.
In this study, we investigated the importance of PAFc in MLL
transcriptional activation and MLL fusion protein transformation.
RESULTS
PAFc Interacts with the CxxC-RD2 Domain of MLL
In order to identify proteins that associate with MLL CxxC-RD2,
we expressed epitope tagged portions of this region transiently
in human embryonic kidney 293 cells (Figure 1A). Flag-tagged
CxxC-RD2 including a nuclear localization signal (NLS) was
immunoprecipitated from transiently transfected 293 cells using
M2 anti-Flag agarose beads. An ‘‘empty’’ expression vector with
Flag epitope tag and NLS was also subjected to immunoprecip-
itation as a nonspecific immunoprecipitation control. Coeluted
proteins were resolved by SDS-PAGE (Figure 1B) and analyzed
by mass spectroscopy. Multiple peptides corresponding to
subunits of PAFc were identified with high probability including
CTR9, LEO1, PAF1, CDC73, and WDR61 that correlated with
silver stained bands at 133 kDa, 105 kDa, 75 kDa, 64 kDa, and
34 kDa, respectively (Figure 1B). Each of the five PAFc subunits
identified by mass spectrometry (PAF1, CDC73, CTR9, LEO1,
and WDR61) was confirmed to coimmunoprecipitate with Myc-
tagged CxxC-RD2 by western blotting in 293 cells (Figure 1C).
To exclude the possibility of a DNA-mediated MLL-PAFc interac-
tion and confirm that the PAFc interaction is preserved in the
context of a fusion protein, we repeated immunoprecipitations
with Myc-tagged CxxC-RD2-AF9 in 293 cells after Benzonase
treatment (see Figure S1A available online). Immunoprecipitation
was preserved in the presence of Benzonase indicating the inter-
action is not DNA dependent (Figure 1D). Furthermore, PAFc
coimmunoprecipitated with Myc-CxxC-RD2-AF9 (Figure 1D), as
well as, Myc-CxxC-RD2 (Figure S1B). These experiments were
repeated with transfection of an expression vector for Flag-
tagged full-length MLL or Flag-tagged MLL-AF9 into 293 cells
followed by immunoprecipitation and western blotting (Figures
1E and 1F). We also confirmed the PAFc interaction by coimmu-
noprecipitation of CDC73 with MLL-ENL in the KOPN8 cell line
(Figure S1C). Together, these experiments show the MLL-
PAFc interaction is maintained both in the context of full-length
Figure 1. MLL Binds to the PAF Complex in a DNA-Independent Manner
(A) Schematic diagram of the full-length MLL protein with key domains indicated. The Flag/HA-tagged CxxC-RD2 MLL fragment used for immunoprecipitation is
shown below. The first and last amino acids of the protein fragments are indicated.
(B) MigR1 and Flag/HA-tagged CxxC-RD2 was expressed in 293 cells and immunoprecipitated. Immunoprecipitates were analyzed by SDS-PAGE and visualized
by silver staining. Arrows indicate bands at the predicted molecular weights of the PAF complex components.
(C) Immunoprecipitation and western blot of the PAF complex after immunoprecipitation of Myc-tagged CxxC-RD2 or Myc tag control from transiently tranfected
293 cells.
(D) The experiment described in (C) was repeated after treatment of the lysate with benzonase to digest DNA, indicating the PAFc interaction with CxxC-RD2 is
DNA independent. Myc-tagged CxxC-RD2-AF9, but not the Myc tag alone, interacts with PAFc subunits, showing that PAFc binding to CxxC-RD2 is maintained
in the presence of the AF9 translocation partner.
(E and F) A full-length Flag-tagged MLL-AF9 fusion protein (E) or Flag-tagged full-length MLL (F) was expressed in 293 cells and immunoprecipitated. The PAF
complex stably associated with full-length MLL fusion protein and MLL as indicated by western blotting. See also Figure S1.
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MLL Requires the PAF Complex for Leukemogenesis(MLLN) as well as in the context of a leukemogenic MLL fusion
protein (Figures 1E and 1F, Figure S1C).
To determine whether the interaction between MLL and PAFc
is direct and to identify the PAFc subunit(s) involved, we bacteri-
ally expressed and purified the MLL CxxC-RD2 region (aa 1115–
1396) and the RD2 region alone (aa 1202–1396) for in vitro
pull-down experiments with bacterially expressed PAF1, LEO1,
CDC73 and CTR9 (expressed as N- and C-terminus proteins
termed CTR9-N and CTR9-C) (Figures 2A and 2B). These in vitro
immunoprecipitations were performed with either CxxC-RD2 or
RD2 with MLL antibodies after incubation with individual compo-
nents of PAFc. Strong interaction of PAF1 with CxxC-RD2 but
not the RD2 region was detected indicating an interaction
between PAF1 and amino acids 1115 and 1201 of MLL
(Figure 2C). These findings are consistent with our in vivo immu-
noprecipitation experiments in which PAFc co-immunoprecipi-
tated with a small fragment of MLL N-terminal to the CxxC
domain (amino acids 1115–1154) (Figure 3, see below). We
also detected a second interaction between CTR9-C and both
the MLL CxxC-RD2 and RD2 regions (Figure 2C). In addition
a weak association of CDC73 with RD2 was also detected.These interactions were confirmed by reciprocal MBP pull
down of CDC73, CTR9-N and CTR9-C, which showed that the
MLL CxxC-RD2 and RD2 regions specifically associated with
CTR9-C, along with a weak interaction detected between RD2
and CDC73 (Figure S2).
We then performed a series of deletion experiments to further
map the MLL residues that participate in the MLL-PAFc inter-
action. Expression vectors for Myc-tagged CxxC-RD2-AF9
deletion mutants spanning the RD2 region of MLL (Figure 3A,
Cx-1154-AF9 through Cx-1357-AF9) were transiently trans-
fected into 293 cells and tested for PAFc interaction. These
experiments reveal a sharp decrease in the MLL-PAFc interac-
tion when C-terminal deletions were made past amino acid
1299 (Figure 3B, compare lanes 6 and 7). To overcome the
residual low level binding of PAFc with proteins deleted at aa
1209 or aa 1258, believed to be the result of pre-CxxC interaction
(Figure 2), we repeated this experiment with a set of deletion
constructs that begin with MLL aa 1180 thereby deleting the
proximal site of PAFc interaction (Figure 3C, Cx-del-1209-AF9
through Cx-del-1357-AF9). These experiments showed PAFc
interaction with MLL is completely eliminated with deletionsCancer Cell 17, 609–621, June 15, 2010 ª2010 Elsevier Inc. 611
Figure 2. PAF1 and CTR9 Bind Directly to
the CxxC-RD2 Region of MLL
(A) Coomassie blue staining of bacterially purified
His-MOCR-tagged CxxC-RD2, RD2, PAF1, LEO1,
and His-MBP-tagged CDC73, CTR9-N, and
CTR9-C. The amino acids of CTR9-N and CTR9-
C are indicated.
(B) Schematic diagram of MLL and bacterially
purified CxxC-RD2 and RD2 regions. Starting
and ending amino acids are indicated.
(C) Immunoprecipitations performed with bacteri-
ally purified recombinant CxxC-RD2 or RD2 and
PAF complex components. Individual PAF
components were incubated with either CxxC-
RD2 or RD2 and immunoprecipitated with MLL
antibodies. PAF components and immunoprecipi-
tated MLL fragments were detected with the indi-
cated antibodies by western blotting. Asterisk
denotes detection of the IgG heavy chain. See
also Figure S2.
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MLL Requires the PAF Complex for Leukemogenesisbeyond aa 1299 (Figure 3D, compare lanes 4 and 5). Together,
our data suggest the MLL-PAFc interaction is multivalent
involving residues of MLL both in the pre-CxxC domain as well
as the RD2 region. Furthermore, the binding of PAFc by both
pre- and post-CxxC domains is consistent with the solution
structure of the MLL CxxC domain (Protein Data Bank [PDB] ID
code 2J2S) (Allen et al., 2006), which shows the DNA binding
CxxC domain coordinates two zinc atoms thereby bringing the
pre- and post-CxxC regions into close opposition (Figure 8D).
PAFc Stimulates Transcriptional Activity by MLL
and MLL Fusion Proteins
We then tested whether PAFc affects the transcriptional output
mediated by MLL and the MLL-AF9 fusion protein. Dual lucif-
erase assays were performed in 293 cells transfected with a lucif-
erase reporter construct under the transcriptional control of the
murine Hoxa9 promoter (Hoxa9-LUC). These experiments
showed that transcriptional activation by wild-type MLL is
enhanced by coexpression of the five PAFc subunits
(Figure 4A). Consistent with our earlier finding (Milne et al.,
2002), we observed a dose-dependent transcriptional activation
of the Hoxa9 promoter by expression of increasing amounts of
MLL-AF9 (Figure 4B). Furthermore, we observed a dose-depen-
dent augmentation of MLL-AF9 dependent transcription of the
Hoxa9 promoter when increasing amounts of PAFc were ex-
pressed. Notably, expression of PAFc alone had little effect on
the Hoxa9 promoter in our assay (Figures 4A and 4B). A similar612 Cancer Cell 17, 609–621, June 15, 2010 ª2010 Elsevier Inc.trend was observed when using an
MLL-AF9 responsive luciferase construct
containing a thymidine kinase promoter
and multimerized Myc E-boxes (Figures
S3A and S3B). Furthermore, we did not
observe augmented transcription when
single PAF components were introduced
(Figure 4C). Deletion of the RD2 region
to amino acid 1258 (which abrogates
PAFc binding [Figure 3]) in an MLL-AF9
fusion protein also diminishes transcrip-tional activation (Figure S3C, compare lanes 5 and 6). Deletion
of RD2 past aa1299 diminishes transactivation despite the
more proximal PAFc interaction site and CxxC domain remaining
intact, demonstrating the importance of the multivalent interac-
tion for transcription. Together, these findings show MLL and
MLL-AF9 synergize with PAFc to augment transcription of target
genes.
MLL Fusion Protein-Mediated Transformation
Is Dependent upon Interaction with PAFc
We then tested whether the transforming potential of MLL fusion
proteins is dependent on the MLL-PAFc interaction. The dele-
tions in the MLL RD2 region tested in immunoprecipitations
described above (Figure 3A) or the pre-CxxC region were cloned
into full-length MLL-AF9 in MSCV-based retroviral vectors
(Figure 5D). These were packaged in Plat-E cells and trans-
duced into 5-FU primed bone marrow and analyzed in methyl-
cellulose replating assays as previously described (Morita
et al., 2000). In brief, transduced cells were cultured under
G418 selection in the presence of IL3, IL6, GM-CSF, and SCF
and colonies quantitated after the first, second and third rounds
of replating (Figure 5A). Western blotting confirmed proteins of
the predicted molecular weights were expressed following
transient transfection of Plat-E cells (Figure 5C). In addition,
real-time polymerase chain reaction (PCR) confirmed expres-
sion of fusion gene mRNA in retrovirally transduced bone
marrow (Figure 5B).
Figure 3. Amino Acids within the RD2
Region Are Necessary for MLL Interaction
with the PAF Complex
(A) Schematic of Myc-tagged CxxC-RD2-AF9
constructs made with serial deletions of the RD2
region. The first and last MLL amino acid retained
in the expression constructs are indicated. All
constructs include the AF9 fusion partner at the
C terminus and Myc tag at the N terminus. The
Cx-1154-AF9 through Cx-1357-AF9 constructs
are named according to the last MLL residue
retained in the fusion protein.
(B) Myc-tagged RD2 deletion constructs
described in (A) were expressed in 293 cells and
then immunoprecipitated. The Myc-tagged MLL
deletion proteins and associated PAF complex
components were detected by western blotting
with the indicated antibodies.
(C) Schematic of a second set of deletion
constructs made through the RD2 region that
also delete the pre-CxxC domain. Cx-del-1209-
AF9 through Cx-del-1357-AF9 were made by
deleting amino acids 1115 through 1179 of MLL.
The amino acids included in each construct are
indicated.
(D) Myc tagged constructs described in (C) were
expressed in 293 cells, immunoprecipitated and
detected as described in (B).
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MLL Requires the PAF Complex for LeukemogenesisAs shown in Figures 5D and 5G, similar numbers of tertiary
colonies were observed when cells were transduced with MLL-
AF9, MLL-1357-AF9, or MLL-1299-AF9. Further deletions of
RD2 that extended more proximally than amino acid 1299, which
markedly reduced PAFc interaction in our immunoprecipitation
experiments (Figure 3), resulted in marked decreases in colonyFigure 4. The PAF Complex Synergizes with MLL and MLL-AF9 to Aug
(A) Luciferase assays were performed with the Hoxa9-LUC reporter construct and
(0–0.6 mg). PAFc includes equal amounts of PAF1, LEO1, CDC73, CTR9, and WD
(0–0.6 mg). All changes are shown relative to lane 1, which includes Hoxa9-LUC
Results of one of more than three representative experiments performed are sho
(B) Experiment was performed as described in (A) except increasing doses of ML
PAFc (0–0.6 mg). Lanes 9–12 show increasing doses of PAFc (0–0.6 mg) in the p
representative experiments is shown.
(C) Luciferase assay performed in transfected 293 cells with the Hoxa9-LUC repo
(lane 7), MLL-AF9 alone (lane 8), MLL-AF9 plus individual PAF components (lanes
Results of one of more than three representative experiments are shown. See alnumbers (Figure 5D and 5G). Importantly, the morphology of
these colonies was also dramatically different. Tertiary colonies
from MLL-AF9, MLL-1357-AF9, and MLL-1299-AF9 all dis-
played a dense, compact morphology indicative of transforma-
tion (Lavau et al., 1997) (Figure 5E). Wright Giemsa-stained
cytospins showed these compact colonies were composed ofment Transcriptional Activity
increasing doses of full-length MLL (lanes 1–4) (0 –0.6 mg) or PAFc (lanes 5–8)
R61. Lanes 9–12 show constant MLL (0.6 mg) with increasing doses of PAFc
and an empty expression vector. Error bars indicate standard deviation (SD).
wn.
L-AF9 (0–0.6 mg) were used in lanes 1–4. Lanes 5–8 show increasing doses of
resence of constant MLL-AF9 (0.6 mg). Error bars indicate ± SD. One of three
rter construct and individual PAFc components in lanes 1–6, the PAF complex
9–13), and MLL-AF9 with the PAF complex (lane 14). Error bars indicate ± SD.
so Figure S3.
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Figure 5. The PAFc Interaction Surface on RD2 Is Necessary for Bone Marrow Transformation by MLL-AF9 Fusion Proteins
(A) Schematic diagram for MLL-AF9 and MLL-AF9 deletion colony forming assay.
(B) Real-time qPCR using primers for the Flag tag on the MLL-AF9 fusion proteins. qPCR was performed on cDNA from bone marrow cells after retroviral trans-
duction. Expression levels are shown relative to MLL-AF9 transduced cells. Error bars indicate ± SD.
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MLL Requires the PAF Complex for Leukemogenesismyeloblasts (Figure 5F). In contrast, transductions of constructs
with more extensive deletions resulted in diffuse colonies
composed of differentiating myeloid cells including monocytes
and macrophages (Figures 5E–5G). Of note, MLL-1258-AF9
retained a limited capacity to produce dense colonies after
tertiary replating, but colony numbers were significantly reduced
compared to MLL-AF9, MLL-1357-AF9, and MLL-1299-AF9
(Figures 5D, 5E, and 5G). In keeping with this, minimal binding
of PAFc was observed with the Cx-1258-AF9 construct
(Figure 3). As expected, MLL-AF9, as well as, 1357 and 1299
deletions markedly upregulated Hoxa9 expression, while forms
incapable of PAFc interaction did not (Figure S4B). The loss of
MLL fusion protein mediated transformation upon deletion of
the pre-CxxC and RD2 domains is comparable to the result
of deleting the DNA binding CxxC domain (MLL-1154-AF9),
which has been previously shown to be required for transforma-
tion (Ayton et al., 2004; Bach et al., 2009). To eliminate the possi-
bility that the deletions introduced prevent interaction with the
enzymatic activities necessary for leukemogenesis, we per-
formed immunoprecipitations with the RD2 deletions constructs
described in Figure 3. These experiments showed that associa-
tion of DOT1L and the pTEFb component, cyclin T1, with AF9 is
maintained in all the deletion constructs used (Figure S4A). This
suggests improper transformation activity is due solely to func-
tions dependent on the RD2 region and not misfolding of
proteins or deficient EAP complex recruitment (Figure S4A). To
confirm PAFc is necessary for MLL-AF9-mediated transforma-
tion, we performed colony assays by transducing bone marrow
cells with MLL-AF9 followed by a second round of transduction
with shRNA retroviruses directed against Cdc73 or Ctr9
(Figure 5H). Both shCdc73 and shCtr9 were confirmed to knock
down Cdc73 and Ctr9, respectively, at the mRNA and protein
level (Figures 5I and 5J). Knockdown of either Cdc73 or Ctr9
resulted in significantly reduced colony formation compared
with a scrambled control shRNA (Figures 5K and 5L). These
data were confirmed with an established MLL-AF9 cell line
(Figures S4C and S4D). We also observed a significantly reduced
proliferation rate when either Cdc73 or Ctr9 was knocked down
in primary cells grown in liquid culture in the presence of IL3 and(C) Western blot for the MSCV-based Flag tagged MLL-AF9 deletion constructs s
precipitated with M2 agarose beads. Proteins were detected with Flag antibodie
(D) The constructs used for the retroviral infection and bone marrow colony ass
Primary, secondary, and tertiary colony counts are shown for methylcellulose
bars indicate SD from duplicate experiments. One of more than three representa
(E) Representative colony morphology is shown for each transduced MLL-AF9 fu
nies indicate differentiation. Scale bars represent 500 mm.
(F) Wright-Giemsa-stained cytospins on cells isolated after the third round of me
(G) Shown are p-iodonitro tetrazolium violet (INT)-stained colonies after three ro
MLL-1299-AF9, and MLL-1357-AF9 transduced bone marrow.
(H) Schematic diagram for MLL-AF9 colony assay with shRNA mediated knock
except for an additional transduction after the second replating with shScram, shC
mycin selection. Colonies were scored after the third plating.
(I) Real-time qPCR was used to confirm knockdown of Cdc73 and Ctr9 mRNA co
(J) Protein lysate was collected from 3T3 cells transduced with shScram, shCdc7
Ctr9 confirms knockdown of the respective proteins. b-actin was probed as a lo
(K) Third round colony counts after transduction with shScram, shCdc73, or shC
(L) Dense colonies are visible from colony assay plates containing shScram tr
shCdc73 and shCtr9 transduced cells.
(M) Cells collected after the second transduction with shRNA were grown in liquid
advantage was observed from MLL-AF9 cells transduced with shScram comparSCF (Figure 5M). Reduced proliferation was also observed when
Cdc73 or Ctr9 was knocked down in the MLL-AF9 cell line
(Figure S4E). Together, these data suggest the PAFc interaction
with MLL is crucially important for both MLL fusion protein
mediated Hox deregulation and transformation.
PAFc Promotes MLL and MLL Fusion Protein
Recruitment to Target Loci
We then examined the localization of PAFc to a leukemogenic
target gene of MLL such as Hoxa9. For these experiments, we
generated cell lines by transducing mouse bone marrow with
either MLL-ENL or E2A-HLF. MLL-ENL cells express much
higher levels of both Hoxa9 and Meis1 compared with E2A-HLF
cells, which are not dependent onHoxa9 expression for transfor-
mation (Ayton and Cleary, 2003) (Figure 6A). We performed
chromatin immunoprecipitation (ChIP) experiments for PAF
components, PAF1, LEO1, CDC73, and CTR9 at the Hoxa9
locus in both cell lines (Figure 6B). These experiments showed
robust binding of MLL-ENL as detected by the ENL antibody in
MLL-ENL cells compared with E2A-HLF cells (Figure 6B).
Furthermore, levels of histone H3K79 di- and trimethylation are
markedly elevated in MLL-ENL cells consistent with ENL medi-
ated recruitment of DOT1L (Mueller et al., 2007). Importantly,
the pattern of binding of PAFc components and MLL-ENL across
the locus is similar, consistent with an MLL-PAFc interaction
(Figure 6B). Sequences downstream of the Hoxa9 locus also
show a dramatic decrease in binding of both MLL-ENL and
PAFc (Figure S5). MLL-ENL binding is somewhat more abundant
upstream and downstream of the transcriptional start site
which may reflect a PAFc independent function for MLL fusion
proteins during transcriptional elongation (Figure 6B). Similarly,
we also observed co-localization of MLL-ENL and PAFc at the
Meis1 locus in MLL-ENL cells, with minimal binding seen in
E2A-HLF cells (Figure 6C). Together, these data suggest that
PAFc localizes with MLL fusion proteins to augment Hox and
Meis1 transcription.
To further evaluate the role of PAFc in transcriptional activa-
tion, we measured the effect of PAFc subunit knockdown on
MLL-AF9 mediated transcriptional activation. Knockdown ofhown in (D). Protein was extracted from transfected Plat-E cells and immuno-
s. The loading control (LC) shows equal loading of protein.
ay are shown on the left. Final amino acids of the MLL deletions are shown.
colony assays performed with the indicated MLL-AF9 fusion proteins. Error
tive experiments is shown.
sion protein. Dense colonies are indicative of transformation while diffuse colo-
thylcellulose plating. Scale bars represent 50 mm.
unds of colony assay replating. Dense red colonies are visible from MLL-AF9,
down of Cdc73 and Ctr9. Colony assays were performed as described in (A)
dc73, and shCtr9 retroviruses followed by plating in methylcellulose with puro-
mpared with shScram after transduction of 3T3 cells. Error bars indicate ± SD.
3, and shCtr9 and separated by SDS-PAGE. Immunoblotting with Cdc73 and
ading control.
tr9. Error bars indicate ± SD.
ansduced cells. Significantly reduced colony numbers were visible from the
culture in the presence of IL3, SCF, and puromycin. A significant proliferative
ed with shCdc73 or shCtr9. Error bars indicate ± SD. See also Figure S4.
Cancer Cell 17, 609–621, June 15, 2010 ª2010 Elsevier Inc. 615
Figure 6. The PAF Complex Colocalizes with MLL-
ENL across the Hoxa9 Locus
(A) qPCR forHoxa9 andMeis1 expression in MLL-ENL and
E2A-HLF cell lines. Error bars indicate ± SD.
(B) ChIP experiment performed in mouse bone marrow cell
lines established with the MLL-ENL or E2A-HLF fusion
protein. MLL-ENL IPs are shown in black and E2A-HLF
IPs are shown in gray. Solid lines indicate the binding
pattern of the component or histone modification listed
to the right. The dotted lines indicate control IgG IPs for
each cell line. The Hoxa9 locus is shown schematically
at the bottom. Error bars indicate ± SD.
(C) Same experiment as described in (B), but binding was
determined on the Meis1 locus. The MLL-ENL IPs are
shown in black (left) and the E2A-HLF IPs are shown in
gray (right). See also Figure S5.
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MLL Requires the PAF Complex for LeukemogenesisPAF1, LEO1, CDC73, and CTR9 was successfully achieved in
HeLa cells with siRNA transfection (Figure 7A). As previously
reported, PAFc knockdown decreases HOXA9 expression in
HeLa cells (Figure 7A) (Zhu et al., 2005b). Importantly, MLL-
AF9 transcriptional activation of Hoxa9-LUC is also impaired
by PAF1, LEO1, CDC73, or CTR9 knockdown (Figure 7B).
Furthermore, we saw an additive effect by knocking down both
CTR9 and LEO1, suggesting MLL fusion proteins require PAFc
for efficient transcription of target genes (Figure 7B).
We then determined the effect of knockdown of the PAF
complex on MLL recruitment to the HOXA9 locus by performing
ChIP assays on HeLa cells after simultaneous knockdown of
CTR9, PAF1, CDC73, and LEO1 (Figure 7C). We observed a
significant decrease in binding of CDC73, PAF1, and LEO1 in
both the promoter and coding region of the HOXA9 locus
following knockdown, as expected, whereas histone H3 levels
remain unchanged or elevated in siPAFc-treated cells (Figure 7D).
PAFc knockdown resulted in a marked decrease in wild-type
MLL binding compared with mock treated cells (Figure 7D),616 Cancer Cell 17, 609–621, June 15, 2010 ª2010 Elsevier Inc.without affecting MLL protein levels (Figure 7C),
suggesting PAFc is necessary for MLL recruit-
ment to HOXA9. Consistent with reduced
binding of MLL, knockdown of the PAF complex
also resulted in a decrease in H3K4 tri-methyla-
tion at the HOXA9 locus (Figure 7D). We also
observed a decrease in histone H3K79 trimethy-
lation (Figure 7D).
PAFc Expression Is Coordinately
Downregulated during Myeloid
Differentiation
The above results suggest that the PAF
complex recruits MLL to the HOXA9 locus and
that modulating PAFc levels may be an impor-
tant mechanism for modulating MLL activity. It
is noteworthy in this regard that a recent unbi-
ased genome-wide siRNA screen identified
PAFc subunits Ctr9, Wdr61, and Rtf1 among
the 30 top genes regulating Oct4 expression
and stem cell renewal (Ding et al., 2009). In
this study PAFc was found to bind to key pluri-
potency genes, which is remarkable becauseMLL fusion protein transformed cells show, in addition to HOX
gene overexpression, a distinctive embryonic stem cell (ESC)-
like pluripotency signature (Somervaille et al., 2009). Further-
more, expression of PAFc subunits is strongly regulated upon
differentiation of ESCs into embryoid bodies (Ding et al., 2009).
Collectively, these findings suggested that PAFc maintains pluri-
potency in hematopoietic progenitors.
We established two differentiation models to explore the
potential role of PAFc in regulation during hematopoietic differ-
entiation. First, we created a conditional AML cell line by immor-
talizing murine bone marrow by transduction with Hoxa9-ER in
the presence of tamoxifen (4-OHT). Upon 4-OHT withdrawal,
these cells undergo differentiation and cell-cycle arrest, which
is largely complete by 120 hr (Figures S6A and S6B). 4-OHT
withdrawal is accompanied by marked upregulation of c-Fos
and c-Jun transcripts indicative of myeloid differentiation (Fig-
ure S6C). Microarray expression profiling was performed in
triplicate at 24, 48, 72, 96, and 120 hr after 4-OHT withdrawal
(only results for 72, 96, and 120 hr are shown in Figure 8A). These
Figure 7. Knockdown of PAFc Reduces MLL-AF9-Mediated Transactivation and MLL Binding to the HOXA9 Locus
(A) siRNA-mediated knockdown of individual PAF components was verified by western blotting. Antibodies used for western blotting are shown on the right and
siRNA is indicated on top.
(B) Luciferase assays were performed with the Hoxa9-LUC reporter construct and MLL-AF9 in HeLa cells after transfection with the indicated siRNA. Luciferase
units are shown relative to the MigR1 control transfected cells. Error bars indicate ± SD.
(C) Simultaneous siRNA mediated knockdown of PAFc (siCTR9, siLEO1, siPAF1, and siCDC73) is shown by western blotting for PAF components after siRNA
transfection of HeLa cells. b-ACTIN was detected as a loading control.
(D) ChIP experiments were performed in HeLa cells after simultaneous knockdown of the PAF components shown in (C). PAF1, LEO1, CDC73, MLLC, H3K4me3,
H3K79me3, and H3 were immunoprecipitated from HeLa cells treated with siPAFc or nontargeting siRNA (Mock). Binding was assessed in both the promoter and
coding region as indicated. A schematic of the HOXA9 locus and location of the primer-probe sets used for qPCR are shown. Error bars indicate ± SD. One of
more than three representative experiments is shown.
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Figure 8. PAFc Is Downregulated during
Differentiation of Hematopoietic Cells
(A) Heat map generated from expression array
data collected from differentiation of the Hoxa9ER
cell line. Data are shown in triplicate for each time
point after tamoxifen withdrawal. Labels indicate
components of the PAF complex, MLL, and MLL
targets, and genes associated with myeloid cell
differentiation.
(B) Expression of PAF components were verified
using qPCR by separately differentiating the
Hoxa9ER cell line by tamoxifen withdrawal. Time
points indicate hours post tamoxifen withdrawal
that RNA was collected. Expression for each
component is shown relative to 0 hr. Error bars
indicate ± SD.
(C) THP-1 cells were transfected with an equal
mixture of PAFc expression vectors or empty
vectors along with a GFP vector at a 5:1 ratio
(PAFc/Empty:GFP). Half were treated with PMA
to induce differentiation. Surface expression of
CD11b was monitored by FACS in the GFP-posi-
tive gated cell population to track differentiation.
Mean fluorescence values are shown for each
sample.
(D) Structure of the CxxC domain and flanking
sequences (PDB code: 2JYI). Solution structure
of MLL CxxC region shows the flanking sequences
of the CxxC domain brought into close juxtaposi-
tion creating a binding surface for both PAF1 and
CTR9 of the PAF complex.
(E) Model for myeloid cell differentiation showing
(top) PAFc dependent recruitment of MLL to
target genes in hematopoietic progenitors (HSC/
myeloblasts). PAFc and MLL recruitment pro-
motes H2B monoubiquitination and H3K4 and
H3K79 methylation resulting in transcriptional acti-
vation. In the middle image, more differentiated
myeloid cells downregulate PAFc expression
resulting in decreased recruitment and transacti-
vation by MLL. As shown in the bottom image, in
leukemic cells harboring MLL fusion proteins, the fusion protein synergizes with PAFc resulting in robust transcriptional activation of target genes. This is asso-
ciated with increased H2B monoubiquitination and histone H3K79 methylation by DOT1L recruited through the MLL fusion partner. See also Figure S6.
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MLL Requires the PAF Complex for Leukemogenesisexperiments showed a marked downregulation of all PAFc
subunits and MLL target genes after induction of differentiation
accompanied by upregulation of genes associated with myeloid
differentiation (Figure 8A). The downregulation of PAFc expres-
sion was confirmed by quantitative PCR (qPCR) in independently
differentiated Hoxa9-ER cells (Figure 8B). We also analyzed the
human HL-60 cell line, which rapidly differentiate into macro-
phages after exposure to phorbol 12-myristate 13-acetate
(PMA) (Figure S6D). PMA treatment also led to a dramatic down-
regulation of PAFc in HL-60 cells (Figure S6E). To test the role of
PAFc in hematopoietic differentiation, we enforced expression of
PAFc in THP-1 cells with or without PMA-induced differentiation.
THP-1 cells were more resistant to differentiation, as determined
by CD11b surface expression, when PAFc was overexpressed
(Figure 8C). Importantly, green fluorescent protein (GFP)-nega-
tive cells showed no significant difference in CD11b expression
(Figure S6F). Together, these data show PAFc expression is
specifically downregulated during myeloid differentiation and
that high-level PAFc expression inhibits differentiation. Thus,618 Cancer Cell 17, 609–621, June 15, 2010 ª2010 Elsevier Inc.PAFc may play an important role in regulating MLL binding to
target genes during differentiation.
DISCUSSION
The work presented here establishes PAFc as an important
cofactor for both transcriptional regulation by MLL as well as
for leukemogenesis mediated by MLL fusion proteins. Interest-
ingly several PAFc components have been previously implicated
in carcinogenesis. Most notably mutations in CDC73 (Parafibro-
min), encoded by HRPT-2 (hereditary hyperparathyroidism
type 2), are responsible for the familial hyperparathyroidism-
jaw tumor (HPT-JT) syndrome (Szabo et al., 1995). HPT-JT is
an autosomal dominant disorder associated with hyperparathy-
roidism (HPT) and a high incidence of parathyroid adenomas,
hyperplasias, and carcinomas as well as renal abnormalities
and uterine tumors (Newey et al., 2009). The mutations in
HRPT-2 are predicted to lead to loss of function due to prema-
ture termination. The chromosome 1q25-q31 region spanning
Cancer Cell
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arising in HPT-JT patients, suggesting that CDC73 functions as
a tumor suppressor (Newey et al., 2009). Consistent with this
role, overexpression of wild-type CDC73, but not a mutant
form found in HPT, blocks cell proliferation and inhibits the
cell-cycle regulator cyclin D1 (Woodard et al., 2005).
However, other studies have implicated overexpression of
PAFc subunits in tumorigenesis. For example, CDC73 overex-
pression in 293FT and COS7 cells increases S-phase entry
and promotes cellular proliferation. This induction of CDC73-
mediated cell dependent proliferation requires the SV40 large
T-antigen, which is directly bound by CDC73 (Iwata et al.,
2007). In a study to identify genes involved in pancreatic tumor
progression, PAF1 was found to be overexpressed as a result
of a double minute amplification involving chromosome 19q13
(Batra et al., 1991). Furthermore, overexpression of PAF1 results
in transformation of NIH 3T3 cells (Moniaux et al., 2006).
The dual roles of CDC73 as a tumor suppressor and an ‘‘aider
and abettor’’ of an oncoprotein (see above) are shared with
another MLL-interacting protein, Menin. Menin interacts with
the N terminus of MLL and is required for transformation by
MLL fusion proteins (Caslini et al., 2007; Yokoyama et al.,
2005). However, MEN1 mutations, which lead to loss of function
of the Menin protein, are found in a variety of endocrine tumors
including parathyroid hyperplasias and adenomas, as well as
pancreatic islet tumor cells establishing Menin as a tumor
suppressor (Chandrasekharappa et al., 1997; Lemmens et al.,
1997). The similarities in the diseases associated with Menin
and PAF subunit mutations (parathyroid and pancreatic islet
tumors) raise the possibility that the mechanisms of oncogenicity
may also be similar, perhaps mediated through cyclin-depen-
dent kinase deregulation as we have previously defined for
Menin (Milne et al., 2005b). These results also suggest that
MLL may play a broader role in tumorigenesis than previously
expected. Additional experiments will be necessary to assess
what role MLL plays in cancers associated with disruption or
amplification of PAF components.
Recently, genome-wide siRNA screens identified components
of the PAF complex as important in maintaining an embryonic
stem cell identity. PAFc was found to bind and regulate several
key pluripotency genes including Oct4 (Ding et al., 2009). Down-
regulation of PAFc caused embryonic stem cell differentiation
suggesting its expression is required to maintain an ESC identity.
Our experiments show a similar coordinate regulation of PAFc
in hematopoietic cells, where PAF component expression is
strongly downregulated during myeloid differentiation (Figure 8).
Recent gene expression profiling experiments have shown that
MLL fusion proteins enforce expression of an ESC gene expres-
sion signature including the expression of Myb, Hmgb3, and
Cbx5, which is necessary for the maintenance of the leukemic
stem cell phenotype (Somervaille et al., 2009). Our data suggest
that PAFc promotes MLL or MLL fusion protein recruitment to
target loci in addition to its known role as a platform for recruit-
ment of RAD6/BRE1 required for histone H2B ubiquitination
and downstream histone H3K4 and H3K79 methylation (Figures
4 and 7). In this way MLL may be properly targeted to gene
promoters in primitive hematopoietic cells, such as myeloblasts,
through interaction with PAFc. During differentiation, downregu-
lation of PAFc may be a mechanism for attenuating MLL bindingto target genes as well as decreasing the histone H2B ubiquitina-
tion that is required for histone H3K4 and H3K79 methylation
(Figure 8E). PAFc expression is high in leukemic cells, allowing
for synergistic activation of key ECS pluripotency genes that
appear to underlie MLL-mediated oncogenesis. It remains to
be seen if MLL plays a role in enforcing the ECS signature that
has been described for other particularly aggressive solid tumors
(Ben-Porath et al., 2008; Gentles et al., 2009).
Our study identified two interaction sites between MLL and
PAFc. The first involves an interaction with the MLL pre-CxxC
domain between residues 1115 and 1154 and the PAFc subunit
PAF1. In addition, under our immunoprecipitation conditions we
observed a second interaction with CTR9 that occurs through
the RD2 region (Figures 2 and 3; Figure S2). These findings
are interesting in light of structural studies showing the CxxC
domain of MLL forms a loop that interacts with DNA (Allen
et al., 2006), thereby bringing the pre-CxxC sequence and the
RD2 region into close juxtaposition in three dimensional space
and creating a single binding surface for PAF1 and CTR9
(Figure 8D). It is intriguing in this regard that the region of RD2
necessary for a stable PAFc interaction is invariably conserved
in MLL translocations, which involve breakpoints no more
proximal than exon 8.
Our transformation assays indicate that both the pre-CxxC
and RD2 interaction domains of MLL are required for transforma-
tion. We hypothesize that although the interaction between MLL
and PAFc can occur through single contact points, it is only fully
stable when both sites are intact. Given the importance of each
of these MLL-PAFc domains for transformation (Figure 5),
small-molecule inhibitors blocking either interaction would be
expected to block oncogenesis by MLL fusion proteins. Given
the general dependence of HOX expression on MLL, it is likely
that inhibitors of this interaction will be effective in other leuke-
mias showing high-level HOX and MEIS1 expression, either as
a result of MLL amplification or conceivably through other path-
ways. The experiments presented here lay the groundwork for
determining the structure of the MLL-PAFc-interacting domain
and the ultimate development of effective therapy based on
targeting this interaction.EXPERIMENTAL PROCEDURES
Cell Culture
293 and HeLa cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1X non-essen-
tial amino acids. MLL-ENL and E2A-HLF cells were cultured in Iscove’s modi-
fied Dulbecco’s medium (IMDM) supplemented with 15% fetal calf serum
(FBS) (Stem Cell Technologies). Hoxa9ER cells were cultured in IMDM supple-
mented with 15% FBS and 0.1% IL3. Plat-E cells were cultured in DMEM
supplemented with 10% FBS. HL-60, THP-1, KOPN8, and K562 cells were
cultured in RPMI-1640 medium supplemented with 10% FBS. Differentiation
of HL-60 and THP-1 cells was induced by 10 nM PMA treatment.
Luciferase Assay
293 cells were transiently transfected with MSCV MLL-AF9 (and derivatives),
CMV-Renilla, and Hoxa9-LUC (or Myc-E box-LUC) constructs using FuGene
6 (Roche) in accordance with the manufacturer’s instructions. Cells were
then serum starved in 0.5% FBS in OPTI-MEM media for 48 hr. Luciferase
assays were performed using the Dual Luciferase assay kit (Promega) accord-
ing to manufacturer’s instructions. Emission was detected using a Monolight
3010 (BD Biosciences).Cancer Cell 17, 609–621, June 15, 2010 ª2010 Elsevier Inc. 619
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MLL Requires the PAF Complex for LeukemogenesisChromatin Immunoprecipitation
ChIP was performed as described previously (Milne et al., 2005a) using
primary antibodies specific for MLLC (gift from Dr. Yali Dou), ENL (gift from
Dr. Robert Slany), histone H3, H3K4 dimethylation, H3K4 trimethylation, and
H3K79 trimethylation (Abcam) and Paf1, Leo1, Parafibromin, and Ctr9 (Bethyl
Laboratories, as described above). Quantitative real-time PCR was performed
on the precipitated DNAs with TaqMan fluorescent labeling with primers and
qPCR probes described in Supplemental Experimental Procedures. Binding
was quantitated as follows:DCT = CT(input)CT(Chromatin IP), % total = 2DCT.
siRNA Knockdown of PAFc
siRNA smart pools were obtained from Dharmacon for CTR9, CDC73, PAF1,
and LEO1. siRNA transfection of HeLa cells was achieved with Lipofectamine
2000 (Invitrogen) according to manufacturer’s instructions for analysis in lucif-
erase assays. Oligofectamine (Invitrogen) was used in accordance with the
manufacturer’s instructions for siRNA transfection of HeLa cells and PAFc
knockdown for ChIP assays.ACCESSION NUMBERS
Microarray data have been deposited in the Gene Expression Omnibus (GEO)
repository from the National Center for Biotechnology Information (NCBI) with
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